Journal article
Efficacy and safety analysis of once per cycle pegfilgrastim and daily lenograstim in patients with breast cancer receiving adjuvant myelosuppressive chemotherapy FEC 100: a pilot study
Therapeutics and clinical risk management, Vol.9(1), pp.457-462
01/01/2013
DOI: 10.2147/TCRM.S48387
PMID: 24255599
Abstract
Background: Neutropenia is a common toxicity in patients receiving myelosuppressive chemotherapy. In this prospective pilot study, we compared the efficacy and safety profiles of pegfilgrastim administered subcutaneously once per cycle and lenograstim administered subcutaneously daily six times per cycle, for primary neutropenia prophylaxis in women with breast cancer receiving adjuvant anthracycline-based chemotherapy.
Materials and methods: Twenty women were enrolled. All patients received epirubicin 100 mg/m(2) with 5-fluorouracil 500 mg/m(2) and cyclophosphamide 500 mg/m(2) on day 1 and every 21 days thereafter, according to the FEC 100 chemotherapy regimen. Eight patients received a single dose of pegfilgrastim on day 2, while 12 patients were treated with daily administration of lenograstim from days five to ten. Absolute neutrophil count and duration of grade 3-4 neutropenia were monitored using seriated blood samples. The incidence of bone pain was evaluated using the visual analog scale (VAS).
Results: The incidence of grade 3-4 neutropenia was 75% in patients who received pegfilgrastim, and 25% in patients who received lenograstim. One case of febrile neutropenia was shown in pegfilgrastim patients. The mean duration of grade 3-4 neutropenia was 2 days in pegfilgrastim group versus 1.4 days in the lenograstim group. Bone pain was present in 37.5% of pegfilgrastim patients versus 58.3% of lenograstim patients. The mean duration of bone pain in the pegfilgrastim group was 4 days versus 6 days in the lenograstim group.
Conclusion: In our experience, a single injection of pegfilgrastim was less effective for controlling neutropenia than six daily injections of lenograstim. The safety profiles of pegfilgrastim and lenograstim were similar with a lower incidence of bone pain in patients treated with pegfilgrastim.
Details
- Title: Subtitle
- Efficacy and safety analysis of once per cycle pegfilgrastim and daily lenograstim in patients with breast cancer receiving adjuvant myelosuppressive chemotherapy FEC 100: a pilot study
- Creators
- Luigi Rossi - Policlinico Umberto IFederica Tomao - Policlinico Umberto IGiuseppe Lo Russo - Univ Rome, Oncol Unit, ICOT Hosp, Policlin Umberto Hosp 1, I-1668 Latina, ItalyAnselmo Papa - Sapienza University of RomeFederica Zoratto - Sapienza University of RomeRaffaella Marzano - Institute of Haematology and Blood TransfusionEnrico Basso - Sapienza University of RomeErika Giordani - Sapienza University of RomeMonica Verrico - Sapienza University of RomeFabio Ricci - Ospedale Santa Maria GorettiGiulia Pasciuti - Don Luigi Liegro Hosp, Oncol Unit, Gaeta, ItalyEdoardo Francini - Policlinico Umberto ISilverio Tomao - Univ Rome, Oncol Unit, ICOT Hosp, Policlin Umberto Hosp 1, I-1668 Latina, Italy
- Resource Type
- Journal article
- Publication Details
- Therapeutics and clinical risk management, Vol.9(1), pp.457-462
- DOI
- 10.2147/TCRM.S48387
- PMID
- 24255599
- ISSN
- 1176-6336
- eISSN
- 1178-203X
- Publisher
- Dove Medical Press Ltd
- Number of pages
- 6
- Language
- English
- Date published
- 01/01/2013
- Academic Unit
- Internal Medicine
- Record Identifier
- 9985221144502771
Metrics
1 Record Views